Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017
New guidelines for screening for tuberculosis and latent tuberculosis infection pre-immunosuppressive therapy in the Netherlands: a targeted and stratified approach Source: International Congress 2019 – Tuberculosis: diagnosis and scores Year: 2019
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Long term treatment outcome in multi drug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Long term treatment out come in multi drug resistant tuberculosis Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen? Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007
Has the time come to shorten TB treatment and TB preventive therapy? Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India? Source: Eur Respir J, 50 (1) 1602182; 10.1183/13993003.02182-2016 Year: 2017
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012